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Abstract
Background: Asthma is associated with enormous healthcare expenditures that include both
direct and indirect costs. It is also associated with the loss of future potential earnings related to
both morbidity and mortality. The objective of the study is to determine the burden of disease
costs associated with asthma.
Methods: We performed a systematic search of MEDLINE, EMBASE, CINAHL, CDSR, OHE-
HEED, and Web of Science Databases between 1966 and 2008.
Results: Sixty-eight studies met the inclusion criteria. Hospitalization and medications were found
to be the most important cost driver of direct costs. Work and school loss accounted for the
greatest percentage of indirect costs. The cost of asthma was correlated with comorbidities, age,
and disease severity.
Conclusion: Despite the availability of effective preventive therapy, costs associated with asthma
are increasing. Strategies including education of patients and physicians, and regular follow-up are
required to reduce the economic burden of asthma.
Background
Asthma is an inflammatory disorder of the lungs that
affects people of all ages and is a significant source of mor-
bidity and mortality worldwide [1,2]. Approximately 300
million people in the world currently have asthma and
recent decades have shown a concerning increase in the
prevalence of this condition in both children and adults
(Figure 1). There has been concerning increase in the prev-
alence asthma in both children and adults) [3]. If the cur-
rent trends continue, it is estimated that there may be an
additional 100 million more asthmatics by 2025 [4].
The economic costs associated with asthma are estimated
to rank as one of the highest among chronic diseases due
to the significant healthcare utilization associated with
this condition. Numerous studies have been published
evaluating the economic burden of asthma on society and
individuals. However, a systematic review of the financial
impact of asthma has not yet been performed [5-8]. The
goal of this systematic review is to evaluate and synthesize
the current literature regarding the economic burden of
asthma. The evaluation of the cost of asthma from both a
social and economic perspective is necessary for an opti-
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mal allocation of resources as well as the betterment of
patient care. This study sought to address the following
question: "What are the direct, indirect (productivity),
and overall costs associated with asthma?"
Methods
Literature Search
A systematic review was conducted to identify English lan-
guage articles published between 1966 and January 2008
in which the costs of asthma were included. Only studies
reported in English (as there was no translator available)
and published literature, were included.
The following electronic databases were searched using
MEDLINE, EMBASE, Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Cochrane Database of
Systematic Reviews (CDSR), Health Economic Evaluation
Database (OHE-HEED), and Web of Science. Search terms
were investigated, including: "asthma", "direct service
costs", "cost of illness", "cost- benefit analysis" and
"health care costs". Duplicate citations were identified
and removed using RefWorks online bibliographic man-
agement tool.
Study Selection
The titles and abstracts of all publications identified
through the primary literature search were independently
reviewed by two investigators. The inclusion and exclu-
sion criteria used for study selection are outlined in Table
1. The total of four non-English abstracts were retrieved
and excluded from the literature search. The full text of all
potentially eligible papers determined after the first level
of screening was reviewed to ensure that each paper met
the inclusion criteria for population and outcomes of
interest.
The types of cost related to illness were divided into direct
and indirect costs and were defined as follows: direct costs
related to direct health service costs and included alterna-
tive treatment/medications, physiotherapy/chiropractic,
peak flow meters, primary care consultations, paid help
for housekeeping, hospital emergency and outpatient
attendance, ambulance and other transportation, and
hospital admissions. Indirect costs were those applicable
to individual patients, their families, and lost opportuni-
ties for work or education. The total cost is an aggregate of
both direct and indirect costs. For cost data from the
United States (US), costs were converted to 2008 US dol-
lars using the medical care component of the consumer
price index from the US Bureau of Labor Statistics.
For cost data from non-US countries, figures were first
converted to 2008 currency values using that country's
consumer price index. Figures were then converted to
2008 US dollars, using currency exchange rates of Austral-
ian dollar (AUD)$1.00 = United States dollar
(USD)$0.637, Canadian dollar (CAD) $1.00 = USD$0.
806, (Euro currency code) EUR€1.00 = USD$1.281, and
Great Britain pound (GBP)£1.00 = USD$1.427. If the year
of the cost data was not reported, it was assumed to be the
publication year of the article. In all cases, both the origi-
nal cost figures provided in the publications as well as the
equivalent costs in 2008 US dollars were reported.
Data Abstraction
A standardized data abstraction form was used for all pub-
lications included in this study. The data abstracted
Trend in prevalence of asthma Figure 1
Trend in prevalence of asthma.
Table 1: Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
• English language ￿ Conference abstracts, case reports, letters, comments, editorials and 
review papers
￿ Studies that consider the costs of asthma from either the individuals', 
the health services', and/or society's perspective
￿ Studies that consider asthma with other comorbidities 
(such as allergies, COPD, etc)
￿ Pharmacodynamic or pharmacokinetic studies
￿ Studies that did not quote costs in the results section
￿ Animal or in vitro studiesBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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included the following information: manuscript authors,
year of publication, study design and duration, patient
characteristics (population, age and gender), method of
cost calculation, direct costs, productivity (indirect) costs,
and total costs. Discrepancies in data abstraction were
resolved by consensus.
Methodological Quality Assessment
The quality of the economic studies was assessed using a
customized version of the Drummond and Jefferson crite-
ria (Table 2) [9]. Quality criteria were scored as positive,
negative, or unclear. Study quality was assessed by one
reviewer and confirmed by a second reviewer. Economic
evaluations that scored 50% or more of the items positive
were defined as studies of high methodological quality,
whereas less than 50% was considered low methodologi-
cal quality. The 50% score was arbitrarily chosen as a
mean cutoff to create binary categories.
Statistical Analysis
Due to the heterogeneity in cost analysis and reporting
across the studies, a quantitative meta-analysis to aggre-
gate cost data could not be performed. Specifically, the
resources used to derive direct healthcare and productivity
costs varied substantially between the studies, as did the
type of currency (USD, GBP, CAD, etc). In the absence of
the ability to complete a meta-analysis, we opted to com-
plete a qualitative analysis. There were not sufficient
homogeneity in terms of participants, interventions, and
the way outcomes were defined and measured, to provide
a meaningful summary for considering the meta-analysis.
Results
Literature Search
The primary literature search identified 2,976 citations.
After removing duplicate citations we were left with 2,073
unique citations for screening. The manual screening of
all 2,073 titles and abstracts yielded 307 articles that con-
tained primary clinical data evaluating the cost of asthma.
Of the 307 full articles retrieved and reviewed by the
investigators, 68 met the inclusion criteria (Figure 2).
Quality Assessment
Most of the studies clearly described the inclusion and
exclusion criteria and the population as well as specifying
the primary outcome measures. The study designs were
cohort (n = 43), cross- sectional studies (n = 22), and case-
control studies (n = 3). Of the 68 studies, only six com-
pleted sensitivity analysis [10-15]. Common perspectives
of an economic evaluation were the societal perspective
(all costs and outcomes experienced by all those who are
significantly affected by the intervention) and the health-
care perspective (only health costs and outcomes). Thirty-
two studies mentioned the perspective (all societal) of the
economic evaluation [10-43]. Twenty-six studies calcu-
lated both direct and indirect costs, which suggests,
although not explicitly mentioned, that these studies also
adopted a societal perspective. Ten studies only calculated
direct medical costs and thus, adopted a healthcare per-
spective. Three studies calculated an incremental cost
effectiveness ratio (ICER) [10,19,21]. The uncertainty of
the outcomes was presented through sensitivity analyses
in six studies [10-15]. The mean score of the quality
assessment regarding the economic evaluation was 6.1
out of a maximum of 10 (Standard Deviation (SD) 1.43;
range, 3 to 9).
Characteristics of the Selected Studies
Of the 68 studies identified in the literature review,
twenty-three used data derived from the US, twenty-five
from European countries, eight from East Asia and the
Pacific regions, five from Canada, and seven were from
other countries. Twenty-eight studies reported mean or
median per patient direct and indirect costs of asthma,
thirteen only reported the total direct costs of asthma, and
fifteen studies reported annual or total asthma related
healthcare expenditures. The economic impact in five
studies was based on charge data (not costs) [25,44-47].
The studies presented in this review used several methods
of cost calculation. The most common method was to
abstract mean patient resource utilization, such as the
number of clinic visits, hospitalizations and procedures,
Table 2: Criteria for evaluating an economic analysis based on Drummond and Jefferson assessment method*
1. Was a well-defined question asked in an answerable form?
2. Was a comprehensive description of the competing alternatives provided?
3. Was there evidence that the program's effectiveness was established?
4. Were all the important and relevant costs & consequences identified?
5. Were costs and consequences measured accurately with appropriate physical units?
6. Were costs and consequences credibly valued?
7. Were costs and consequences adjusted for differential timing?
8. Was an incremental analysis of costs and consequences of alternatives performed?
9. Was a sensitivity analysis performed?
10. Did the presentation and discussion of the study results include all issues of concern to users?
*Note: All items have three possible responses, Yes (+), Cannot tell (N/A) and No (-).BMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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through chart reviews or insurance databases, and to com-
bine these data with the mean unit costs of each resource,
derived from local or national accounting databases. An
alternative method was to follow a cohort of subjects via
a cost-accounting system to capture the charges or costs
incurred over time in the management of asthma symp-
toms.
Direct Versus Indirect Costs of Asthma
Cost of asthma includes the components of both direct
and indirect costs. Direct costs include inpatient care,
emergency visits, physician visits, nursing services, ambu-
lance use, drugs and devices, blood and diagnostic tests,
research, and education. Indirect costs or morbidity costs
include school days lost, traveling, waiting time, and lost
productivity for the caretaker of asthmatic children. Direct
costs have been shown to exceed indirect costs, and the
major components of the direct medical costs found were
pharmacological expenditures and hospital admissions.
An increase in direct medical costs can potentially lead to
a reduced total cost of care if it results in a disproportion-
ately greater reduction in indirect costs due to improved
clinical outcomes. In our systematic review, nine studies
have found that the direct cost of asthma accounted for
the greatest part (53–100%) of the overall cost
[11,14,18,29,42,47-50] (Table 3). Of these, five were con-
sidered high quality studies. However, some of the
reviewed cost-of-illness studies estimated the healthcare
costs associated with asthma, but they took the broader
societal perspective and also included the impact of mor-
bidity and mortality on employment, productivity and
other social costs. In five studies, the indirect costs greatly
exceeded the direct costs [13,17,22,51,52]. The quality of
Results of systematic literature search Figure 2
Results of systematic literature search.
Total citations identified
(n= 2976) 
Potentially relevant studies 
(n=304)
x Asthma with other comorbidities 
xNon English text 
xConference abstracts, case reports, letters, 
anonymous authors, comments, meta-
analysis, editorials and review papers
Included Studies 
(n=68)
Studies that met the 
inclusion criteria (n=177) x No cost analysis
xNo Pharmacodynamic or pharmacokinetic 
studies
xNo asthma management or asthma 
intervention studies
Table 3: Studies were direct cost exceeded indirect cost of asthma
References 
No.
Country Study 
duration
Sample size Total direct 
cost/person
Mean 
annual 
direct cost/
person
%T o t a l  
indirect 
cost
Total cost Mean 
annual cost/
person
Institutional studies
11 US 1 yr 401 - 3,307 65 1,801 - 4,158
18 Canada 1 yr 149 196,898ϕ - 74 67,729 264,627 -
-- -- -
42 Canada 1 yr 339 - 1,200 x 88 157 - 1,357
752 y 100 - 752
85 z 56 66 151
Regional studies
47 Australia 1 yr 1.2 m 273 - 77 81 354 -
National studies
14 US 1 yr 4.7 m 7,301 - 88 955 8,256 -
29 Canada 1 yr N/A * 397 - 61 257 654 -
48 Switzerland 1 yr N/A * 860 - 61 553 1,413 -
49 US 1 yr N/A * 3,822 - 53 3,367 7,189 -
58 US 10 yrs 14.2 m 8,665 - 57 6,583 15,248 -
All costs are converted and adjusted into 2008 US dollars
Cost in regional and national studies are in million of dollars
Φ: of total study sample size, x = societal perspective, y = ministry of health perspective, z = patient perspective
m: million; yr: year; N/A*: data not availableBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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all but one of the above studies was also high [51] and
indirect costs accounted for 52–75% of the overall costs
(Table 4).
Direct Cost of Asthma
Hospital Admission
In this systematic review, the largest amount of direct costs
found were those allocated to in-patient hospitalization,
accounting for 52 to 86% of the overall asthma-related
costs in seven studies, [28,30,38,42,53-55] and 47 to 67%
of total direct costs in another five studies [14,15,
20,48,49] (Table 5).
There are several factors that can contribute to higher total
hospital costs. Two studies found the following variables
correlated significantly with higher hospital costs: older
patients, significant comorbidities, intensive care unit
(ICU) admission, increasing severity, and prolonged
length of stay. In both studies, a small proportion of asth-
matics accounted for a large proportion of the total hospi-
tal costs [36,56]. A similar result has also been observed in
another study, possibly because of poorly controlled
patients with more severe asthma [14].
Stanford and associates reported resources such as nursing
care, respiratory therapy, and ED-specific supplies along
with equipment use and physician fees to account for the
majority of hospital costs of asthma; 44%, 11% and 53%
of the costs, respectively [36]. The results of the cost esti-
mation for asthma hospitalization in Quebec for the year
1994/95 indicated that of the total cost of $23.3 million,
the greatest proportion was accounted for by pediatric
patients ($11 million) [57]. Similar findings in a retro-
spective cohort study also suggested that although teach-
ing hospitals in their study were not found to have higher
charges, children's hospitals appeared to be more expen-
sive due to the inherent responsibilities of a teaching hos-
pital, but also due to the fact that they act as regional
referral centers with specialized services for children [25].
A patient's characteristics can also affect the cost of hospi-
talization. In a study conducted in France, the cost of a
hospital stay was compared between a well-managed asth-
matic group and a poorly managed one before hospitali-
zation based upon guidelines (11 criteria judged by
experts). The poorly managed group was older, tended to
include more smokers, spent half as much time in ambu-
latory care, and had a shorter length of hospitalization.
The cost of a hospital stay was found to be 1.72 times
higher in the better managed group, due mainly to the dif-
ferences in the length of the hospital stay. However, in the
unmanaged group, non conformity to the treatment for
the attack resulted in a cost excess ($4,900 vs. $4,065 p <
0.05) [58].
Over a ten-year period in United States, hospital inpatient
care represented the largest component cost of direct med-
ical expenditures in 1985. However, in 1994, medications
were reported to be the largest component cost of direct
medical expenditures. The annual estimates increased
from approximately $1.4 billion (1985 adjusted dollars)
to $2.5 billion. This increase was due to an estimated
103.2% increase in total number of prescribed medica-
tions and an estimated 169.3% increase in average unit
cost per medication [50].
Asthma Cost and Hospital Characteristics
Our review showed that there are associations between
asthma-related costs and the stratification of hospitals by
geographic region, ownership, location, and teaching sta-
tus. In this systematic review, five studies explored the
relationship between hospital "characteristics" and the
cost of asthma. A large, comprehensive administrative
database examined the association of selected hospital
Table 4: Studies were indirect cost exceeded direct cost of asthma
References 
No.
Country Study 
duration
Sample size Total 
indirect cost
Mean annual 
indirect cost/
person
%T o t a l  d i r e c t  
cost
Total cost Mean annual 
cost per 
person
Institutional studies
13 Spain 1 yr 333 - 2,749 69 1,221 - 3,970
17 Italy 1 yr 500 - 1,068 52 970 - 2,038
22* US 1 yr 638 - n/a 55 488 - 727
50 Denmark 1 yr 115 822,067 - 67 402,668 1,224,735 -
National studies
51 Germany 1 yr 52,794 n/a - 75 - 4.43 b -
All costs are converted and adjusted into 2008 US dollars
* n/a: data not available; b: billion; yr: yearBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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characteristics with cost among pediatric patients with
asthma and its severity by hospital type in the state of New
York. Hospital types were classified into teaching versus
non-teaching and private versus public. They reported the
mean cost of asthma to be higher in private hospitals,
($1,868 vs. $1,771) and non-teaching hospitals ($1,876
vs. $1,528). Although after adjustments for patient and
hospital covariates, the differences in mean cost between
public and private hospitals did not remain significant
[59]. In contrast, a high-quality study conducted at a
teaching hospital in an urban setting in Canada, found
total operating expenses per in-hospital patient day to be
$681.70 for teaching hospitals and $496.81 for non-
teaching hospitals, for the fiscal year 1990 to 1991 [18].
However, in another cohort study, after adjusting for
patient and hospital characteristics, they found no differ-
ences in hospital charges between teaching and non-
teaching hospitals [25].
In a cross-sectional study, the mean total charges, after
adjusting for significant covariates including severity of
illness, income, and payer, were found to be significantly
higher at investor owned ($4,203) as opposed to non-
profit ($3,640) or public hospitals ($3,620). Further-
more, the average charges were found to be higher at
urban teaching ($4,230) and lower at rural institutions
($2,910) compared with urban non-teaching hospitals
($3,424) [44]. However, a five year-population-based
study yielded contradictory findings regarding costs per
hospital discharge. In this study, public hospitals reported
the highest costs per discharge when compared with not-
for-profit and for-profit hospitals ($656.84 vs. $514.08
and $411.95, respectively). They included the asthma
patients discharged with referral to an outpatient unit,
who generally had higher costs than those patients dis-
charged who had made a full recovery [32].
Asthma Medications
Medications were found to be another major contributor
to the cost of asthma. Eighteen studies reported "medica-
tions" as forming the largest proportion of the direct costs
related to asthma, accounting for 38%–89% of the total
cost [11,13,15,16,19,22,23,27-29,35,37,43,46,47,52,56,
60] (Table 6).
In a large-scale study, the costs of asthma medication were
found to be the largest cost factor in children ($382.09 or
41.3% of total direct cost) whilst it was reported as being
Table 5: Studies that represented inpatient care cost as the largest proportion of total direct cost or total asthma related cost
References 
No.
Country Study 
duration
Sample 
size
Cost of inpatient care/person Total 
direct cost
Total 
asthma 
related cost/
person
Total 
asthma 
related cost
Mean SD 95%CI %
Institutional studies
15 Canada 1 yr 940 614¥ -- - 1 , 4 2 1 - -
28 Australia 1 yr 245 397 - - - - 779 -
30 France 1 yr 17 ** 229 282.4 - 52 - - 6,856
38 UK 1 yr 29* 439 816 0–2,895 57 - - 773
42 Canada 1 yr 339 591 - - 77ψ -7 6 6 -
48 Switzerland 1 yr 589 928 - - 47ξ 1,779 - -
52 Spain 3 mo 126 1,932 - 1,529–2,353 83 2,338 - -
53 France 1 yr 94** 64,675ϕ - - 86 - - 745,847
Regional studies
54 US 1 yr 530,000 7.8 m - - - - - 20 m
National studies
14 US 1 yr 4.7 m 4 b - 2 – 6 b 54 7 b - -
20 Singapore 1 yr 27,164** 12 m - - - 25 m 346 49 m
49 US 5 yrs 463,500** 1.6 b - - 67 4 b - 7.2 b
All costs are converted and adjusted into 2008 US dollars
¥ from the societal perspective; * Number of the trial families admitted to hospital, out of 94 trials; **average number of hospitalization for asthma 
in one year; ξ: Hospital care found to be a major cost factor only in the adult group of the study;
ψ: From ministry of health (MOH) perspective. It accounted 43% of total cost from a societal perspective;
ϕ:of total study sample size; m: million; b: billion; mo: month; yr: yearBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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lower in adults. Furthermore, hospital care was found to
be a major cost factor in adult patients ($928.28,
accounted for 46.5% of total direct cost) [48]. Besides age,
severity of disease was found to be another factor affecting
the cost of medications. In a high quality study in Switzer-
land between 1996 and 1997, the cost categories differed
greatly between those with and without exacerbations. In
the latter, medication costs represented 70% while hospi-
talization costs were 10% of total cost. However, in those
with exacerbations, medication costs contributed only
28%, but hospitalization costs contributed 63% of total
costs [35]. Moreover, differences in the perspectives of
patients, society, and the Ministry of Health could affect
both their behaviors and the asthma related costs. In two
different high quality studies, the cost of asthma in Can-
ada was estimated from the perspectives of society, the
Ministry of Health, and the patient. Hospital admissions
were reported to be the highest component of total cost in
adults from a societal perspective in the one study [15],
and the highest component of total cost in children from
both societal and the Ministry of Health's perspectives in
the second study [42]. However, medication costs were
found to be the largest single component of direct costs
from the patient's perspective, in both studies [15,42].
Besides hospitalization and medications, some patients
were shown to have much higher or lower costs, depend-
ing on the actual utilization of medical services.
Physician Visits/Outpatient Clinic
Outpatient services provided by hospitals may be in the
form of clinics, or be more similar in practice to a group
medical practice within a hospital. These outpatient visits
provide the same kind of care that is provided in a physi-
cian's office; it is thus anticipated that the costs will be the
same. In a recent retrospective study, the largest propor-
tion of direct costs was due to outpatient clinic costs
(48.5%) and the majority (~76%) of this cost was due to
completing pulmonary function tests (44%) and skin-
prick tests (34%) [61]. Similarly, two other studies
Table 6: Studies that represented medication costs as the largest component of total asthma related cost
References 
No.
Country Study 
duration
Sample size Cost of medication/person Total direct 
cost
Total cost Mean 
annual cost/
person
Mean SD 95%CI %
Institutional studies
11 US 1 yr 401 2,070 50 4,101
13 Spain 1 yr 333 552 454 45 1,221 3,971
15 Canada 1 yr 940 56¥ 82
16 Italy 1 yr 446 240 181–299 47 ν 1,186
19 Turkey 1 yr 118 1,388 109 81 1,713
22 US 1 yr 638 141 53 ψ 488 727
23 France 1 yr 234 - 60–75 ξ -
27 Sweden 1 yr 220 463 56 822 0.62 b 2,655
28 Australia 1 yr 245 55 89¢ 235 ¥
35 Switzerland 1 yr 263 814 735 70 1,156
55 Thailand 1 yr 183 72 111 47 154 §
60 Estonia 1 yr 1,423 154,140ϕ 53 ψ 3.60 m 203
Regional studies
37 US 1 yr 25,614 - 38 679
47 Australia 1 yr 1.2 m 147 m 54 273 m 354 m
National studies
29 Canada 1 yr N/A* 164 m - 404 m
43 US 1 yr 2.52 m 495 m 66 43 2.3 b
51 Germany 1 yr 52,794 0.58 b 84 0.69 b 2.74 b
All costs are converted and adjusted into 2008 US dollars
Cost information of study 46 was not available
¥: From the patient's perspective; ¥: Total annual cost per person of asthma management to individuals; ν: 47% of mean annual direct cost per 
patient;
¢ :The major component of the individual cost; N/A*: All asthmatic patients in 1990; ξ: 75% of stage 2&3 and 60% of stages 1&4 (the total amount is 
not available); §: hospital resource utilization; ψ: 53% of total medical expenditure; ϕ: of total study sample size; m: million, b: billion; yr: yearBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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reported "physician visits or office-based visits" to be the
largest expense of asthma related direct costs accounting
for 55–58% of direct costs [21,39]. Likewise, a cost-of-ill-
ness study in United States over the 10-year period from
1985–1994 reported an increase in total estimated annual
asthma-related physician office visits combined with an
increase in the average charge per visit, which accounted
for an 82% relative increase in office visit expenditures
[50].
Cost of Asthma and Category of Service
Unscheduled consultations found to be major compo-
nents of primary care costs associated with the manage-
ment of asthma. Prescribed medication for maintenance
treatment was also found to contribute significantly to the
total asthma related costs. However, the results from stud-
ies comparing these two services have given conflicting
results. In a large high-quality cohort study in eight coun-
tries from the Asia-Pacific region, direct costs of asthma
were estimated as: total costs, urgent (unscheduled) ver-
sus maintenance costs, and drug versus non-drug costs.
The study reported that the urgent care costs were higher
than maintenance costs in the participating areas: Singa-
pore, Hong Kong, Malaysia and China, representing 62%
of the total costs [31]. In contrast costs of maintenance
therapy were reported to be more important in adults and
children, respectively accounting for 67% of total health
services in one study [62] and 55% and 73% of the total
direct costs of treatment in another study [63]. None of
the two latter studies were of high quality and thus, may
not be a true reflection of the overall economic impact of
asthma.
Another cohort study classified the encounters into four
categories of services: non-urgent outpatient visit, urgent
care visit, pharmacy refills, and hospitalization. This study
showed that two-thirds of the asthma care costs were
attributable to non-urgent outpatient care and prescrip-
tions; only one third were found to be attributable to
urgent care and hospitalizations. This was possibly due to
better access of enrollees to preventive asthma care, result-
ing in fewer acute exacerbations requiring emergency
department (ED) visits or hospitalizations [33]. Similarly,
a recent study conducted in Taiwan found that almost
three-fourths of asthma related costs was attributable to
office and outpatient care; and only one-fourth were
attributable to urgent care and hospitalization. The
authors felt their findings to be reasonable given the regu-
lar clinical and follow up these patients received, which
diminished the need for urgent care and hospitalization
[40].
Insurance Coverage
In this systematic review, we found that adequate insur-
ance coverage in patients with asthma correlated with a
reduced use of urgent or emergent care. Two studies inves-
tigated the influence of insurance coverage on medical
resource utilization and costs. In the first, which was a
high-quality cohort study, the patients who were insured
reported for every visit that they used more primary care
services (at higher costs) and less emergency department
services (at lower costs) than patients who were unin-
sured. However, patients who were uninsured on some
visits were reported to have higher primary care, emer-
gency department, and inpatient costs than patients in
any other insurance category, suggesting a greater severity
of illness among these patients. An additional reason is
that they also lacked insurance coverage to purchase more
appropriate controller asthma medications [39]. Simi-
larly, in the second study, patients with supplementary
insurance coverage reported a lower overall resource utili-
zation rate. Total costs amounted to $2,446 for patients
without supplementary insurance coverage and $2,092
for patients with such coverage [64].
Indirect Cost of Asthma
Economic assessments of asthma included in the
reviewed studies indicated that decreased productivity at
work and school represent a considerable proportion of
the disease burden, specifically adding to indirect health
costs. To accurately assess health-related work impair-
ment, it is important to take into account both time lost
from work, or absenteeism, as well as loss of productivity
while at work. Productivity losses were measured as the
days lost from productive activities because of asthma, the
days that patients worked despite asthma symptoms
(restricted days), and travel and waiting time associated
with receiving outpatient asthma care. Twelve studies
included loss of productivity due to absenteeism from
work/school as the largest single indirect cost [11,13-
16,20,27,42,43,48,51,65], and loss of school/work days
was found to be the largest category of indirect cost in
eight studies [10,18,21-23,26,49,50] (Table 7). The indi-
rect cost of asthma was not evaluated in eleven studies
[19,30,34,35,39,54,62,64,66-68]. The quality of the
eleven studies, except for two of them, was all estimated
to be above average.
Children with asthma have much higher indirect costs
than the average child as the costs of parents missing work
due to the child's asthma is also an indirect cost. In a study
conducted in Hungary, high consumption of indirect
resources was observed for both the adult and pediatric
population. However, the indirect costs represented a
much higher proportion of total costs for pediatric
patients compared with adult patients (52% vs. 21%).
Furthermore, there was a statistically significant increase
in the cost of lost work between parents of patients with
good control and parents of patients with poor control
[26].BMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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Cost of Asthma and the Associated Risk Factors
Severity
In our systematic review, disease of greater severity, was
associated with a higher total costs. Twenty-two studies
suggested more severe disease to be a major factor influ-
encing the increase in asthma- related costs [11,13, 15,
17,19,21,23,27,30,31,35,36,41,46,51,53,54,58,62,66,67
] (Table 8). In two studies, the severity of illness was clas-
sified into mild, moderate and severe categories. The first
study, conducted in Spain, reported that the per-patient
cost ratio of asthma increased to 1 to 1.5 to 2.6 for the
three levels of asthma. The second study, from US,
reported that the per-patient cost ratios increased to 1 to
1.4 to 2.4 for pediatric patients and 1 to 1.5 to 2.9 for
adult asthma patients having good, moderate, and poor
asthma control, respectively [13,26]. Similarly in a study
in the US over a two year period, asthma costs per patient
were found to be five times higher for those whose asthma
was categorized as severe than for those with mild asthma
($1,579 vs. $298) on a per patient basis [67]. Another
Spanish study revealed that the cost of a moderate asthma
exacerbation was 4-fold greater than that of a mild exacer-
bation, and the cost of a severe exacerbation as much as 12
times that of a mild exacerbation. The cost analysis,
according to prior asthma severity, also indicated that the
cost attributed to a patient with severe persistent asthma
was 2.2 times higher than that of an exacerbation in a
patient with intermittent asthma. This indicates that
severe exacerbations were found to be more harmful to
the patient and much more costly to the health system
regardless of the prior disease severity [53]. In one high
quality study in the US, dividing patients with persistent
asthma into mild, moderate, and severe categories
showed that the average annual direct cost of a patient
with severe, persistent asthma to be 1.3 times the cost of a
patient with moderate, persistent asthma and 1.7 times
the cost of a patient with mild, persistent asthma [21].
Moreover, another high-quality study completed in Spain
between 1994 and 1995 reported the costs of asthma for
patients with severe disease to be almost three-times
Table 7: Studies that represented loss of productivity due to absenteeism from work/school as the largest proportion of total indirect 
costs
References No. Country Study duration Sample size Productivity loss/person Total indirect 
cost
Total asthma 
related cost
Mean SD 95%CI %
Institutional studies
10 US 1 yr 3528 83 - - - 148 -
11 US 1 yr 401 1,370 - - 61 2,234 -
13 Spain 1 yr 333 553,569 ϕ - - - 915,674 -
15¥ Canada 1 yr 940 935 - - 92 1,018 -
1,411 - - 50 2,836 -
16 Italy 1 yr 527 416 - 261–573 53 663 -
18 Canada 1 yr 149 44,623 - - - 67,729 -
21 US 1 yr 443 1,437 3732 - - 1,788 -
23*F r a n c e 1  y r 3 1 8 - - - - -
26 Hungary 1 yr 378 x 540 - - - 1,132 -
711 y 170 - - - 810 -
27 Sweden 1 yr 115 1,399 - - 76 1,778 -
42 Canada 1 yr 339 66 - - 44 150 -
50 Denmark 1 yr 115 760,853 ϕ - - 62 822,067 1.2 m
National studies
14 US 1 yr 35000 315 m - 113–517 33 955 m 8,256 m
20 Singapore 1 yr 142,300 18.5 m - - 37 24.31 m 49.36 m
43 US 1 yr 2.52 b 821 m - - - 1,124 m 2.3 b
48 Switzerland 1 yr N/A 414 m - - 75 551 m 1,413 m
49 US 1 yr N/A 1,448 m - - - 4.2 b 7.2 b
58 US 10 yrs 14.2 m 1,902 m - - - 6,583 m 15,248 m
All costs are converted and adjusted into 2008 US dollars
* Cost information of studies 65 and 22 were not available
¥: 92% from the patient perspective and 50% from the societal perspective; ϕ: of total study sample size; N/A: Number of asthmatics patients in US 
in 1985
x: adult and pediatric patients, y: pediatrics; m: million; b: billionB
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Table 8: Studies that found influence of severity on asthma- related costs
Severity
Intermittent Mild Moderate Severe Subgroups
References 
No.
Country Study 
duration
Total n n Cost n Cost n Cost n cost
Institutional
11 US 1 yr 401 - - 200 3339 137 5,716 64 16,168
13 Spain 1 yr 333 - - 140 257,979 116 385,239 77 679,091
15 Canada 1 yr 940 - - 1,799 2,466 4,344 Societal 
perspective
- 256 744 459 862 225 1,192 Ministry 
perspective
- 877 1,079 1,763 patient 
perspective
19 Turkey 1 yr 118 4 202 54 1,006 46 1,954 14 4,081
21 US 1 yr 3002 - - 787 5,390 1194 6,838 988 9,020
23 France 1 yr 318 32 435 78 1,134 91 1,977 33 4,598
27 Sweden 1 yr 115 53 359 62 4,473
30 France 1 yr 261 - - 108 606 58 704 63 561 Good control
- 1,184 808 1,426 Moderate 
control
- 329 741 4,476 Poor control
35 Switzerland 1 yr 422 14 511 31 1,440 42 3,487 72 5,228
36 US 1 yr 3223 515 2,875 431 3,973 101 6,303 27 19,820
46 Thailand 1 yr 511 - 104 - 125 - 182 - 224
52 Spain 3 mo 126 - - - 515 - 1,926 - 5,544
53 US 1 yr 1038 - - - 536 - 1,255 - 627 Good control
- 354 651 200 1,119 347 1.214 Moderate 
control
- 1,903 1,953 1,808 Poor control
57 France 1 yr 169 66 3,942 53 4,608 Group P
23 4,527 27 9,574 Group A
62 Turkey 1 yr 183 - - 124 806 36+23 1,729
67 US 2 yrs 2213 - - 1,007 463 237 374 969 2,362
41 Australia 1 yr 193 No visits One visit/yr 2 Visits/yr >2 Visits/yr Urgent visit Hospitalization
n$ n $ n $ n $ n $n $
35 80 26 195 38 207 55 202 31 298 8 819
Regional
50 Denmark 1 yr 115 16 755 47 8,856 48 13,201 4 40,677
17 Italy 1 yr 500 174 1,165 134 1,692 153 2,507 39 5,382
National
66 11 countries 1 yr 1201 - 1,143 - 1,113 - 1,213 - 1,480
10 countries 1124
All costs are converted and adjusted into 2008 US dollars
Group P: not managed; group A: managed; * Cost information of studies 31 and 22 were not available.BMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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higher than for those with moderate asthma and five-
times higher for those with mild illness [13]. In 1999, a
retrospective cohort analysis of a representative data set of
12,203 patients with asthma in the United Kingdom (UK)
made a comparison of healthcare costs between patients
who had an asthma attack and those who did not. Average
total costs per patient was reported to be 3.53 times higher
in the group who reported asthma attacks than in the non-
attack group, indicating that the cost of managing patients
who experienced an acute asthma attack impinged heavily
on healthcare budgets [69]. Similarly, in a large-scale
Swiss study, total costs in patients with attacks were 2.38
more compared with patients without attacks [48].
Poor Asthma Management
The mean annual cost per patient increased as the level of
disease control decreased. Seven studies reported that
"poor asthma control" was associated with an increase in
healthcare and elevated costs [14,16,26,30,31,51,54]
(Table 9). All but one were rated as a high quality study.
In a study by Lai et al, the relationship between asthma
control status, measured using a derived Asthma Control
Test (ACT) score, and utilization of healthcare and its cost
in eight Asia-Pacific areas were explored. ACT questions
asked patients to report for the previous four weeks, limi-
tations to activities; shortness of breath; nighttime awak-
ening; use of rescue medication; and perception of
control. Completion of the ACT resulted in a potential
score of between 5 and 25; a score of ≥ 20 indicated "well-
controlled" asthma and a score of <15 suggested "poorly
controlled" asthma. The mean per-patient annual cost of
asthma management for patients with a derived ACT of
<15 was $861; $319 for patients with a derived score 15–
19; and $193 for patients with a derived ACT score of ≥ 20.
A higher derived ACT score was associated with a signifi-
cantly lower annual expenditure on asthma management.
This provides new evidence quantifying the link between
asthma control and unscheduled healthcare resource use
and cost. Poor asthma control was found to be associated
with a greater likelihood for hospitalization and unsched-
uled physician visits in the previous year. Not surprisingly
higher asthma related costs were also found [31].
Disability Status and Comorbidity Conditions
An association between asthma patients with co morbidi-
ties and higher costs was also found. Three studies
reported that costs increased significantly amongst
asthma patients with comorbidities/comorbid conditions
[24,35,54]. In a high quality study, diseases such as hemi-
plegia, neurological disorders, psychosis, and acquired
immune deficiency syndrome (AIDS), which were associ-
ated with significant resource use in general, were found
to be highly significant cost drivers for the asthma cohort.
More importantly, low-cost high prevalence diseases such
as lower respiratory tract infections were also found to be
significant cost drivers as well [34].
The high costs among unemployed or retired patients
constituted an important finding because these patients
were found to be most likely to have a poor overall prog-
nosis in terms of morbidity and mortality. In a study con-
ducted in Switzerland, the highest total costs were
Table 9: Studies that found increased cost of asthma associated with poorly controlled asthma
Reference No. Country Study duration n Asthma control Cost stratified by severity
Low Moderate High
50 Denmark 1 yr 39 Well treated 8,948
76 Poorly treated 11,523
53 US 1 yr 515 Well treated 536 651 1,903
294 Intermediate 1,255 1,117 1,954
128 Poorly treated 627 1,214 1,808
14 Italy 1 yr Well treated 593
527 Poorly treated 2,099
20 Hungary 1 yr 248 Pediatrics Well treated 973
98 Intermediate 1,374
10 Poorly treated 2,651
352 Adults Well treated 554
254 Intermediate 861
88 Poorly treated 1,632
All costs are converted and adjusted into 2008 US dollars
Cost information of studies 30 and 31 were not availableBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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observed among jobless patients and those receiving disa-
bility payments [63]. Similarly, in another study con-
ducted in Canada, illness-related disability was found to
be the largest component of indirect costs ($76 million)
[29]. In another high quality study, total costs among
worker's with asthma, with disability claims were reported
to be approximately three times higher than among disa-
bility claimants in the employee control sample ($14,827
vs. $5,280). Although treatment for asthma itself
accounted for 16% or more of total costs, comorbid con-
ditions accounted for an additional 13% or more. For
workers with asthma, wage-replacement costs for work-
days lost (40%) were found to be almost as much as med-
ical care (43%) [10]. Similarly, in a high quality study,
disability pensioners and homemakers were found to
have higher costs than severely ill patients [15].
Age
Age was also found to have an association with the cost of
asthma, but there were conflicting reports. Younger age
was found to be a significant predictor of higher costs in
seven studies [12,14,22,42,62,70,71]. However, seven
studies reported "older age" to be significantly more likely
to have higher costs [15,27,36,39,54,56,58], or costs of
asthma to be increased as patients' age increased
[35,45,48,52,60,66]. One study reported asthma-derived
direct costs to be double in elderly compared to younger
asthma patients, mainly due to higher costs of hospitali-
zation and medication [68]. Two other cohort studies
found totally different results. The first, conducted in the
US, after stratifying patients into five age groups (5–9, 10–
14, 15–19, 20–29, and 30–34) years, found that adoles-
cents (15–19) years old had both lower inpatient and out-
patient (primary care, urgent and nonurgent emergency
department services) costs than either younger or older
patients (pvalue < 0.05 and pvalue < 0.01, respectively)
[39]. The second, conducted in eight Asia Pacific area
countries, found extremes of age (<10 yrs and >60 yrs) to
be significantly predictive of higher asthma related costs
[31].
Gender
Gender was also found to have an association with the
cost of asthma. Females were found to have higher direct
costs than males, independently of the severity of disease
in three high-quality studies [13,16,37].
Race
We also found a correlation between race and the cost of
asthma. Identified Caucasian patients, particularly
females in a high-quality study over one year, were found
to have significantly more primary care visits (at higher
costs) compared with African Americans [14]. In contrast,
African-American females were found to have signifi-
cantly more emergency department visits and costs com-
pared with Caucasian patients [39].
Other Factors
Besides disease severity, current use of preventive drugs,
current use of emergency services and/or current hospital-
ization was found to be the predictors of costs of child-
hood asthma [62]. Not surprisingly ICU admission was
found to be significantly associated, with higher total hos-
pital costs [56]. A study in Canada reported smoking and
drug plans to be significant explanatory factors of higher
costs from different societal, Ministry of Health, and
patient perspectives. The annual cost per patient in this
study varied from $1,255 in young non smokers with no
drug plan and mild disease to $5,032 in older smokers
with drug plans and more severe disease [15]. Statistically
significant predictors of higher total costs in another study
by Ungar (2001) were worse symptoms and season of par-
ticipation [42]. Also, in another high quality cost of illness
study, use of peak expiratory flow rate meters, low-income
status, non-Caucasian race, and longer duration of asthma
were found to have a significant association with increas-
ing cost [22]. Two studies reported free access to health-
care as a significant risk factor for increased cost of asthma
[30,53]. In addition, one study reported that costs
increased significantly with the occurrence of asthma
symptoms in the previous year as well as possible pre-
scribed inhaled corticosteroids [54]. A cohort study in the
US found the number of β-agonists and oral corticoster-
oid prescriptions to be significantly associated with higher
costs [34]. A study in Switzerland reported use of control-
ler therapy versus symptom relief medication and involve-
ment of a pulmonologist in management was associated
with an 80% and 30% increase in direct medical asthma
costs, respectively [35]. Another Italian study reported
asthma subjects, with chronic cough and sputum produc-
tion to have higher costs compared to subjects without the
symptoms. Moreover, the risk of having high direct med-
ical expenditures was reported to be significantly higher
for blue-collar workers as compared to workers of a higher
socio economic status [16]. Finally, multiple regression
analyses of the 2,052 exacerbations included in the eco-
nomic analysis showed that the cost of exacerbations was
significantly affected by country (P < 0.0001). Mean costs
were found to be significantly higher in secondary care
($1,994) than primary care ($657, p = 0.0003) [66].
Discussion
Economic evaluations of asthma have been performed in
many countries. But there are only limited population
based studies. The studies reported here are difficult to
compare because of differences in study designs, defini-
tions of costs, and different time periods. The present sys-
tematic review was aimed at identifying the evidenceBMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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concerning the economic burden of asthma, as there have
been no other systematic reviews in the literature that
have reviewed this field and it is a highly emergent aspect
of health-services management.
Asthma is associated with enormous healthcare expendi-
tures that includes both direct costs, in the form of hospi-
talizations and medications, and indirect costs, in the
form of loss of work which is a combination of directly
missed days of work/school that occur during the exacer-
bation and the loss of future potential earnings associated
with both morbidity and mortality.
Indirect costs in some studies constitute a major portion
of health related costs, and were identified to be higher
than direct costs in six studies [13,15,17,22,51,52]. How-
ever, not all of the reviewed studies have evaluated the
indirect costs associated with asthmatic patients. There-
fore, additional studies are necessary to provide a clearer
description of these indirect costs and their contribution
to the total cost of care.
In contrast, nine cost of illness studies reported that the
direct costs of asthma, associated with hospitalization or
medications, to be higher than the indirect costs of
asthma [11,14,18,29,42,47-50]. This may possibly be
explained by the costs of hospitalization and medication
as the most important cost among direct costs.
The significant contribution of direct healthcare costs due
to hospitalization in studies is not surprising given the
inherent high costs associated with acute care versus
ambulatory care [14,15,20,28,30,36,38,42,48-50,53-
57,65,72]. Variations in the cost of hospitalization are
likely related to the differences in the socioeconomic envi-
ronment, that is, the difference in the gross national
income per capita, or more specifically differences in sal-
ary costs in different countries.
The fact that the cost of asthma medications is the largest
proportion of direct costs of asthma, is likely explained by
the fact that there are a relatively large proportion of
patients with asthma of whom only a minority are admit-
ted to hospital. In addition the combination of frequent
use, the higher cost of newer asthma drugs [11,13,
15,19,22,23,27-29,35,37,43,46,47,52,56,60], the smaller
proportion in hospital costs and the higher proportion in
medication costs seen in some studies could also point to
better control of asthma. It also likely reflects a rise in the
prevalence of asthma. Furthermore, lower hospital costs
can partly be explained by an overall trend towards
shorter length of stay in hospital [52].
The predominance of non urgent office and outpatient
costs compared to hospitalization and emergency depart-
ment charges reported in five reviewed studies might be
explained by the better access of patients to preventive
asthma care or fewer acute exacerbations requiring hospi-
talization or emergency care visits [33,37,39,40,43]. Like-
wise, the predominance of urgent costs might be due to
the poor control of the disease in countries where primary
care is less well developed, leading to more urgent health-
care utilization.
Hospital type and characteristics were reported to have
been associated with differences in charges for asthma
hospitalizations. Teaching hospitals were found to have
higher charges compared with non-teaching hospitals
[44]. This is likely due to higher costs associated with
teaching hospitals in terms of funding due to teaching and
also the overall higher acuity and greater likelihood of
more complex patients being cared for in these hospitals.
The higher costs associated with patients admitted to
medical centers and regional hospitals than other patients
admitted to district hospitals can be explained partly by
the tendency of medical centers and regional hospitals to
receive a relatively higher proportion of patients suffering
from more serious illnesses than district hospitals [32].
In contrast, two studies in the US found no significant dif-
ferences in costs and charges between teaching and non-
teaching hospitals suggesting that, even with the responsi-
bility of providing education, research, and care for indi-
gent patients, teaching hospitals are competitive in their
treatment of asthma [25,59]. One possible reason con-
tributing to the differences in costs based on hospital
ownership might be attributable to a hospital's levels of
efficiency and also with the exception of mechanical ven-
tilation of asthma patients; usual care of asthma patients
irrespective of location is not associated with a high level
of technology [32].
Not surprisingly costs of asthma care were found to
increase in the presence of exacerbations and with disease
of greater severity [11,13,15,17,19,21-23,27,30,31,35,36,
41,46,51,53,54,58,62,66,67].
The reasons that children with asthma reported higher
healthcare costs compared to non-asthma conditions
could be related to: higher use of ambulatory care and
medications for upper respiratory tract infections or con-
ditions that can act synergistically with asthma (such as
respiratory infections, otitis, sinusitis, etc), the use of day-
care centers, experiencing more severe asthma on average
and higher healthcare use in general, and misclassification
of asthma-related encounters as "non-asthma"
[24,25,30,40-43,57,62,70,71]. However, for adults, the
increased total costs and increased costs per affected per-
son could be explained by either an increase in the sever-BMC Pulmonary Medicine 2009, 9:24 http://www.biomedcentral.com/1471-2466/9/24
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ity of asthma or a decrease in the use of effective
healthcare resources. In elderly patients with comorbidi-
ties, such as congestive heart failure, which may deterio-
rate with asthma exacerbations, have been associated with
a sharp increase in the costs derived from the disease
[36,56,68].
Several studies have investigated a variety of potential risk
factors associated with a higher risk of direct or indirect
costs of asthma including: both old and young ages,
female gender, smoking, co-morbid conditions, chronic
cough and phlegm, use of peak expiratory flow rate
meters, free access to healthcare, low-income status, non-
white race, asthma symptoms in the past year, longer
duration of asthma, controller therapy versus quick ther-
apy, involvement of a pulmonologist in diagnosis or treat-
ment, number of β-agonists and oral corticosteroid
prescriptions, and whether inhaled corticosteroids had
been prescribed before. The findings that females with
asthma spend more on annual asthma care than males
might be because of a higher use of acute care facilities due
to inadequate medication and poor inhalation skills, or it
might be interpreted as females confronted with a chronic
illness are more concerned than males and thus, seek
medical care more often and have more medicine pre-
scribed.
Three more recent studies have been reviewed in this sys-
tematic review; however, their findings didn't contribute
further to the previous results [73-75].
Despite the availability of effective preventive therapy,
hospital admissions from acute asthma are increasing.
This might demonstrate that patients with acute asthma
exacerbations continue to be treated inappropriately prior
to hospital admission.
Conclusion
In summary, asthma is not only associated with patient
specific impairment, but it is also associated with a signif-
icant cost to society. The comparison of studies assessing
direct and indirect costs of asthma underscores important
facts: hospitalization and medications have been found to
be the most important cost driver of direct costs, while
work/school absenteeism accounted for the greatest per-
centage of indirect costs. The cost of asthma was found to
be strongly correlated with comorbidities, age, severity of
disease, and some other factors. It was also found to vary
significantly by hospital ownership, location, and teach-
ing status. A large variation of asthma control can partly
be explained by variation in guideline adherence to med-
ication use and deficits of patients' management espe-
cially as it relates to access to patient education. Particular
interventional strategies such as intensive education of
patients and physicians, regular follow-up and pre-
planned homecare are required to improve quality of life
as well as decrease the economic burdens of asthma.
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